January 25, 2005
From the ALS Association

Representatives of Novartis have shared information with The ALS Association regarding their current Phase II drug trial of TCH 346 for ALS.

Unfortunately, Novartis officials have advised that the drug has shown no impact on the rate of progression or survival of ALS patients.   We are all very disappointed about this outcome.

Novartis has demonstrated its commitment to ALS/MND research throughout the trial process of this drug.  There have been regular information sessions to keep us informed.  ALSA has shared that information with its constituents.

The ALS Association wishes Novartis well in its ongoing interest and research into neurological disease and ALS, and we look forward to new discoveries and trials in the future.   Also, we look forward to continuing our relationship with Novartis in the interests of people living with ALS and the fight against this disease.